Mobile

Irbesartan versus Placebo in Combination with Standard Cardiovascular Protection ACE-I Therapy with Ramipril for the Treatment of Hypertensive Albuminuria in Subjects at Elevated Cardiovascular Risk

Mise à jour : Il y a 5 ans
Référence : EUCTR2004-000022-75

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare the change in albumin excretion rate (AER) measured in overnight urine collections from baseline to week 20 between groups assigned to ramipril and irbesartan or to ramipril and placebo in hypertensive subjects with increased cardiovascular risk.

Critère d'inclusion

  • Albuminuria in hypertensive subjects at increased cardiovascular risk

Liens